Anti-Depressant market to Witness Robust Expansion Throughout the Forecast Period 2021-2026

Comments · 188 Views

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value.

Stratview Research has published a new report titled “Anti-Depressant market” which is segmented By Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist, Reuptake Inhibitors, Others), End-User (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others), and Region.

As per the study, the Anti-Depressant market is projected to grow from USD 14.3 billion in 2020 to USD 17.5 billion by 2026 at a CAGR of around 3.4% during the forecast period.

Report Highlights

This report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can affect the market dynamics of the industry. It provides thorough analysis of the market segments which include products, applications, and competitor analysis.

The market is bifurcated into various segments. Below given is the segment-wise analysis -

By depressive disorder, the anti-depressant market has been bifurcated into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others. Under these, the major depressive disorder segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment growth can be an increasing number of people suffering from depression.

By region, the market in North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR during the assessment period. The regional growth is primarily attributed to the high prevalence of depression, expanding geriatric populace, and presence of key market players such as Bristol Myers Squibb (US) and Eli Lilly and Company (US). The market growth in the Asia-Pacific region is expected to be driven by rising awareness among consumers regarding depression disease in developing countries, particularly China and India.

Who are the Key Players in the Market?

This report provides market intelligence in the most comprehensive way. It also provides critical insights into the key players active in the market, that will enable strategic decision-making for the existing market players as well as those willing to enter the market. The following are the key players activen in the Anti-Depressant market:

  • Alkermes (Ireland)
  • Allergan, Inc. (Ireland)
  • Bristol Myers Squibb (US)
  • Eli Lilly and Company (US)
  • GlaxoSmithKline plc (UK)
  • Lundbeck A/S (Denmark)
  • The Merck Group (Germany)
  • Pfizer Inc. (US)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • The Takeda Pharmaceutical Company Limited (Japan)

Request a sample here- https://www.stratviewresearch.com/Request-Sample/2418/Anti-Depressant-Market.html#form

Custom Research:

Stratview research delivers custom research services across the sectors. In case of any custom research requirements, please send your inquiry to sales@stratviewresearch.com. Or connect with our experts at +1-313-307-4176.

About Us

Stratview Research is a global market research firm, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with insightful market data to aid strategic decision making. These exclusive reports are the result of exclusive research methodology and are available for key industries such as chemicals, composites, advanced materials, technology, renewable energy, and more.

Comments